Sparsentan Granted Orphan Drug Designation for IgA Nephropathy Treatment
Monday, December 02, 2024
Renalys Pharma has announced that sparsentan has received Orphan Drug Designation in Japan for the treatment of primary IgA nephropathy.
IgA nephropathy is a rare kidney condition where abnormal IgA proteins accumulate in the kidneys, leading to inflammation and impaired function. It is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in Japan. Despite its severity, there are currently no approved treatments for this condition, highlighting the urgent need for effective therapies.
The designation, granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) on 27 November 2024, supports therapies for rare conditions affecting fewer than 50,000 patients in Japan and for which there is a significant unmet medical need.
Sparsentan, in-licensed from Travere Therapeutics, Inc., is currently undergoing phase III clinical trials in Japan. The Orphan Drug Designation offers benefits such as priority review, which is expected to accelerate the regulatory approval process for marketing authorisation.
Primary IgA nephropathy is a leading cause of kidney failure, characterised by deposits of abnormal IgA proteins in the kidneys.
These deposits can cause inflammation and reduced kidney function. Japan currently lacks approved treatments for this condition, which underscores the urgent need for innovative therapies.
Renalys Pharma is advancing the development of sparsentan in Japan and across Asia, leveraging phase III data from global clinical studies. The company holds exclusive rights to develop and commercialise the drug in several Asian countries, including South Korea, Taiwan, and Southeast Asia.
Sparsentan, marketed as FILSPARI® in the United States, received full FDA approval in September 2024 to treat adults with primary IgA nephropathy at risk of disease progression.
Renalys Pharma aims to address the healthcare burden posed by chronic kidney diseases such as IgA nephropathy, which significantly impacts the Japanese healthcare system.
The company remains focused on bringing innovative solutions to patients as quickly as possible.
Source: renalys.com
